Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.91 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$756.89M
Enterprise ValueAU$1.62B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)54.5
Beta0.56
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.03
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.14Price Target Upside38.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$799.43M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth enlarges the clinic and hospital footprint's throughput, improving fixed-cost absorption in an equipment‑intensive business. Over 2–6 months this supports better scale economics, bargaining power with payers and capacity to fund targeted reinvestment.
High Gross MarginA very high gross margin indicates strong pricing power and low variable costs per scan, reflecting efficient utilization of imaging assets. This structural margin advantage supports operating leverage as volumes grow and provides room to absorb SG&A or invest in advanced modalities.
Improved LeverageLower leverage versus prior levels reduces refinancing and solvency risk for a capital‑intensive operator. Improved debt metrics enhance access to credit for equipment purchases and M&A, preserving strategic optionality to expand clinic networks across community and hospital settings.
Bears Say
Weak Net Profit MarginsExtremely low net margins show difficulty converting high revenue and gross profit into shareholder returns, likely from high overhead, financing or one-off costs. Persistently thin net profitability limits retained earnings, capital allocation flexibility and long‑term return generation.
Declining Free Cash FlowA large fall in free cash flow undermines the company's ability to self‑fund capex and service debt in an equipment‑heavy industry. If sustained, this pressures liquidity, may force external financing, and can slow clinic expansion or upgrades that drive future revenue.
Low Return On EquityROE near zero implies shareholders receive minimal returns despite growth, signaling inefficiencies in converting invested capital into profits. Over months this weak ROE can constrain capital attraction, reduce reinvestment incentives, and invite strategic review of asset allocation.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$1.91 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$756.89M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 74 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.033 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.14 (38.94% Upside)
AU$3.14 (38.94% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$24.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.14
▲(38.94% Upside)
Technical Analysis
Healius Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---